tetano
Editor, Senior Moderator
Sci Rep
. 2023 Jun 20;13(1):9976.
doi: 10.1038/s41598-023-36998-1. Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients
Mayuko Kawabe[SUP] #[/SUP][SUP] 1 [/SUP], Takafumi Kuroda[SUP] #[/SUP][SUP] 1 [/SUP], Izumi Yamamoto[SUP] 2 [/SUP], Akimitsu Kobayashi[SUP] 1 [/SUP], Yutaro Ohki[SUP] 1 [/SUP], Ayaka Hayashi[SUP] 1 [/SUP], Fumihiko Urabe[SUP] 3 [/SUP], Jun Miki[SUP] 3 [/SUP], Hiroki Yamada[SUP] 3 [/SUP], Takahiro Kimura[SUP] 3 [/SUP], Nanae Matsuo[SUP] 1 [/SUP], Yudo Tanno[SUP] 1 [/SUP], Tetsuya Horino[SUP] 4 [/SUP], Ichiro Ohkido[SUP] 1 [/SUP], Hiroyasu Yamamoto[SUP] 1 [/SUP], Takashi Yokoo[SUP] 1 [/SUP]
Affiliations
The humoral response of kidney transplant recipients (KTR) to the mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is generally poor. We evaluated the booster effect of the third dose (D3) of two SARS-CoV-2 mRNA vaccines 6 months after the second dose (D2) in Japanese KTR. The anti-spike (anti-S) antibody titer 1 and 3 months after the D3 was evaluated in 82 Japanese KTR. The primary endpoint was the seropositivity rate, and factors associated with the lack of a response were evaluated in a logistic regression model. Overall, the anti-S antibody seropositivity rate 1 and 3 months after the D3 was 74.7% and 76.0%. The anti-S antibody titers after the first and second doses were higher in patients vaccinated with the mRNA-1273 than with the BNT162b2 vaccine. Among the 38 KTR who were seronegative 5 months after the D2, 18 (47.4%) became seropositive following the D3. Factors associated with a non-response were mycophenolic acid dose, post-transplant duration, hemoglobin, and lymphocyte count. A humoral response 1 and 3 months after the D3 was obtained in ~ 75% of KTR, but 20% were non-responders. Additional studies are needed to clarify the factors hindering a vaccine response.
. 2023 Jun 20;13(1):9976.
doi: 10.1038/s41598-023-36998-1. Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients
Mayuko Kawabe[SUP] #[/SUP][SUP] 1 [/SUP], Takafumi Kuroda[SUP] #[/SUP][SUP] 1 [/SUP], Izumi Yamamoto[SUP] 2 [/SUP], Akimitsu Kobayashi[SUP] 1 [/SUP], Yutaro Ohki[SUP] 1 [/SUP], Ayaka Hayashi[SUP] 1 [/SUP], Fumihiko Urabe[SUP] 3 [/SUP], Jun Miki[SUP] 3 [/SUP], Hiroki Yamada[SUP] 3 [/SUP], Takahiro Kimura[SUP] 3 [/SUP], Nanae Matsuo[SUP] 1 [/SUP], Yudo Tanno[SUP] 1 [/SUP], Tetsuya Horino[SUP] 4 [/SUP], Ichiro Ohkido[SUP] 1 [/SUP], Hiroyasu Yamamoto[SUP] 1 [/SUP], Takashi Yokoo[SUP] 1 [/SUP]
Affiliations
- PMID: 37340001
- DOI: 10.1038/s41598-023-36998-1
The humoral response of kidney transplant recipients (KTR) to the mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is generally poor. We evaluated the booster effect of the third dose (D3) of two SARS-CoV-2 mRNA vaccines 6 months after the second dose (D2) in Japanese KTR. The anti-spike (anti-S) antibody titer 1 and 3 months after the D3 was evaluated in 82 Japanese KTR. The primary endpoint was the seropositivity rate, and factors associated with the lack of a response were evaluated in a logistic regression model. Overall, the anti-S antibody seropositivity rate 1 and 3 months after the D3 was 74.7% and 76.0%. The anti-S antibody titers after the first and second doses were higher in patients vaccinated with the mRNA-1273 than with the BNT162b2 vaccine. Among the 38 KTR who were seronegative 5 months after the D2, 18 (47.4%) became seropositive following the D3. Factors associated with a non-response were mycophenolic acid dose, post-transplant duration, hemoglobin, and lymphocyte count. A humoral response 1 and 3 months after the D3 was obtained in ~ 75% of KTR, but 20% were non-responders. Additional studies are needed to clarify the factors hindering a vaccine response.